OBSTETRIC-FETAL PHARMACOLOGY RESEARCH UNITS NETWORK

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 德克萨斯大学医学部(UTMB)有能力作为产科-胎儿药理学研究单位(OPRU)网络的成员积极参与。加里·汉金斯，医学博士，以PI的身份，负责拟议的关于在妊娠期使用降血糖药物治疗糖尿病的临床试验。他在多个NIH多中心试验中拥有丰富的经验，例如，非整倍体风险的早期和中期评估(FAST)、产前硫酸镁的有益效果研究(BEAM)和阴道超声环扎试验。汉金斯博士通过参与UTMB的地区母婴健康计划(RMCHP)，成功地招募和留住了患者。所有RMCHP诊所都遵循由汉金斯博士领导的母胎医学部制定的方案。每年有12,000多名孕妇在妇幼保健计划诊所系统内得到护理，其中约7,000人在妇幼保健院分娩。药理学/药代动力学(PK)合作研究员马哈茂德·S·艾哈迈德博士在他的研究中利用人胎盘和衍生制剂方面拥有超过25年的专业经验。艾哈迈德博士是胎盘受体、胎盘受体的天然配体和介导的反应，以及滋养层组织释放hCG的机制方面的实验室先驱。他们调查了体外和体内长期服用阿片类药物对胎盘生理学和母婴结局的影响。利用胎盘小叶的双重灌流，他们展示了外流蛋白和胎盘代谢酶对胎盘阿片类药物转移的PK的影响。他们确认胎盘芳香酶是一种药物代谢酶，并正在研究其多态性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The University of Texas Medical Branch (UTMB) has the capability to participate actively as a member of the Obstetric-Fetal Pharmacology Research Units (OPRU) Network. Gary Hankins, MD, as PI, is responsible for the proposed clinical trial on the use of hypoglycemic drugs in the treatment of diabetes during pregnancy. He has extensive experience within several NIH multicenter trials, eg, First and Second Trimester Evaluation of Risk of Aneuploidy (FASTER), Beneficial Effects of Antenatal Magnesium Sulfate Study (BEAM), and the Vaginal Ultrasound Cerclage Trial. Dr. Hankins has achieved successful patient recruitment and retention by involvement with UTMB's Regional Maternal & Child Health Program (RMCHP). All RMCHP clinics follow protocols established by the Maternal-Fetal Medicine division, headed by Dr. Hankins. Over 12,000 pregnant women are cared for annually within the RMCHP clinic system, approximately 7,000 of whom deliver at UTMB. The Pharmacology/Pharmacokinetics (PK) Co-Investigator, Mahmoud S. Ahmed, PhD, has over 25 years of expertise in utilizing human placenta and derived preparations in his investigations. Dr. Ahmed is a laboratory-pioneered investigator in placental receptors, their natural ligands and mediated responses, as well as the mechanism of hCG release from trophoblast tissue. They investigated the effects of in vitro and in vivo chronic administration of opiates on placental physiology and maternal-neonatal outcome. Utilizing dual perfusion of placental lobule, they demonstrated the influence of efflux protein and placental metabolic [enzymes on the PK for placental transfer of opiates. They identified placental aromatase as a drug-metabolizing enzyme and are investigating its polymorphism.